Abstract 1200P
Background
Multiphoton microscopy is an innovative procedure that enables the histological examination of tissue samples without the prior production of thin sections using paraffin or freeze preparation. As a result, time-critical examinations in the operating room can be considerably simplified and accelerated. As part of the study, a mobile tissue scanner will be analyzed using resection tissue from multiple surgery departments. The image quality, the staining protocols and the laser parameters will be analyzed.
Methods
Multiphoton microscopy uses a laser source to specifically utilize a non-linear optical effect in order to scan individual depth levels in tissue blocks. The tissue only needs to be briefly immersed in dye to obtain H&E images that are directly available in digital format. The planned sample size of the study includes 400 samples from neurosurgery, general surgery, gynecology, urology and dermatology. Both healthy and diseased samples are analyzed. Depending on the department, the resections are either directly transported from the operating room to our lab in a nutrient solution or are first sent to the pathology department for examination, where a pathologist decides which tissue can be used for the study.
Results
The study has provided the first promising images from various tumor types such as melanoma, colon cancer and an infiltrating malignant tumor in uterus tissue. The staining protocol is now much more reliable and usually takes 2:30 min. The multiphoton microscope achieves a scanning speed of 4 min/cm2, with a further acceleration potential to 30 s/cm2. The image quality is better than that of frozen sections and shows no artefacts due to freezing or cutting (e.g. cracks & folds).
Conclusions
In initial trials with resection tissue, multiphoton microscopy has proven to be a reliable and fast measurement method that could enable H&E imaging of tissue in less than 10 minutes. In the later stage of our study, the images will be compared directly with the intraoperative frozen sections and the microscope will also be tested directly in the operating room and the pathology department. We also plan to increase the imaging speed to reach the full potential of our imaging modality.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work the author(s) used www.deepl.com in order to translate some of the text. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
Histolution GmbH.
Funding
Histolution GmbH.
Disclosure
M. Homs Soler: Financial Interests, Personal, Stocks/Shares, Shareholder: Histolution GmbH. All other authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10